J&J presented the new analysis from three Phase III trials of Caplyta in MDD.

A new medical large language model (LLM) achieved over 91% accuracy in identifying female participants diagnosed with major ...

The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...

The American College of Lifestyle Medicine, or ACLM, released a new expert consensus statement on the role of lifestyle ...

EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIs Now commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to ...

Adjunctive omega-3 therapy failed to improve moderate-to-severe depression more than place ...

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

New TMS biomarkers combined with machine learning accurately classified major depressive disorder. Learn more about this ...

Internet use is part of daily life for many people in work, social interaction, entertainment, shopping, and many other ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

Click Therapeutics’ CEO discusses the first FDA-cleared depression app, migraine treatment breakthrough, and digital ...